New treatment shows promise for resistant breast cancer

A new treatment involving an antibody-drug combination has shown promise for women with metastatic breast cancer that does not respond to standard therapies. The drug, patritumab deruxtecan, caused significant tumor shrinkage in more than half of the patients who received it.

How the treatment works

Patritumab deruxtecan functions like a "guided missile," targeting specific proteins on cancer cells while minimizing damage to healthy tissue. This targeted approach helps it bypass common resistance mechanisms that make other treatments less effective.

Clinical trial results

In clinical trials, the drug demonstrated a durable remission in many patients, offering new hope for those who have exhausted other treatment options. These results have sparked interest among oncologists and researchers looking for more effective therapies.

Mammogram recommendations

Starting at age 50, it is recommended that women have a mammogram every two years to screen for breast cancer. Screening aims to detect cancer at an early stage when it is more treatable.

Purpose of screening

The purpose of breast cancer screening is to identify the disease before symptoms appear, increasing the chances of successful treatment. Early detection can lead to better outcomes and more treatment options.